Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, March 28, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, reported today that Pyxis Oncology’s Compensation Committee of the Board of Directors granted restricted stock units with respect to an aggregate of 39,680 shares of Pyxis Oncology’s common stock and stock options to purchase an aggregate of 49,600 shares of Pyxis Oncology’s common stock to a newly hired employee. The awards were granted under the Pyxis Oncology, Inc. 2022 Inducement Plan with a grant date of March 28, 2024, as an inducement material to the new employee entering employment with Pyxis Oncology, in accordance with Nasdaq Listing Rule 5635(c)(4).